Been LB, Suurmeijer A, Cobben D, et al. 18F-FLT-PET in oncology: current status and opportunities[J]. Eur J Nucl Med Mol Imaging, 2004, 31: 1 659-1 672.
[3]
Baudot PH, Jacue M, Robin M. Effect of a diaza-polyoxa-macro-bicyclic complexing reagent on the urinary elimination of lead in lead-poisoned rate[J]. Toxicol Appl Pharmacol, 1977, 41: 113-115.
[4]
Chal YT, Da Hl JR. Thin layer chromatographic detection of Kryptofix 2.2.2 in the routine synthesis of 18F-FDG[J]. Nucl Med Biol, 1989, 16: 385-387.
Garmestani K, Link JM, Krohn KA. Synthesis of tritiated dibotane and cryptand[2.2.2 ] [J]. J Labelled Compounds and Radiopharmaceuticals, 1990, 28(10): 1 171-1 178.
[7]
Kruse MA, Rees SE, Watkins GL. Quality control of Kryptofix or tetrabutyammonium ion in FDG sample by quantitative HPLC analysis proceeding of 47th annual meeting [J]. Nucl Med, 2000, 27(2): 148.
Ying Ma, Huang BX, Channing MA, et al. Quantification of Kryptofix 2.2.2 in 2-18F-FDG and other radiopharmaceutials by LC/ MS/ MS [J]. Nucl Med Biol, 2002, 29: 125-129.
